Review of the novelties presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II);Revisión de las novedades presentadas en el XXVI Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (II)

Revista de Neurologia

Volumn 52, Issue 5, 2011, Pages 289-299

  Fernández Fernández, Óscar ^a   Álvarez Cermeño, José C ^c   Arbizu Urdiain, Txomin ^d   Arroyo González, Rafael ^e   Arnal García, Carmen ^f   Casanova Estruch, Bonaventura ^g   Carmen Calles Hernandez M ^h   Coret Ferrer, Francisco ⁱ   Comabella, Manuel ^b   García Merino, Juan A ^j   De Las Heras, Virginia ^e   Izquierdo, Guillermo ^k   Meca Lallana, José E ^l   Muñoz García, Delicias ^m   Olascoaga, Javier ⁿ   Oreja Guevara, Celia ^o   Prieto, José M ^p   Rodríguez Antigüedad, Alfredo ^q   Tintoré, Mar ^l   Montalban, Xavier ^b  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^m HOSPITAL XERAL CÍES   (Spain)

ⁿ HOSPITAL DONOSTIA   (Spain)

^o HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^p University Hospital of Santiago de Compostela   (Spain)

^q HOSPITAL DE BASURTO   (Spain)

more..

Author keywords

Monoclonal antibodies; Multiple sclerosis; Safety; Treatment

Indexed keywords

ALEMTUZUMAB; DACLIZUMAB; GLATIRAMER; NATALIZUMAB; OCRELIZUMAB; MONOCLONAL ANTIBODY;

ANTIBODY DETECTION; BEHAVIOR THERAPY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; HUMAN; JC VIRUS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; DIFFERENTIAL DIAGNOSIS; HUMAN EXPERIMENT; ORGANIZATION; PATHOLOGY; PATHOPHYSIOLOGY; SWEDEN;

ANTIBODIES, MONOCLONAL; CONGRESSES AS TOPIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; MULTIPLE SCLEROSIS; SWEDEN; THERAPEUTIC HUMAN EXPERIMENTATION;

EID: 79952347214     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5205.2011027     Document Type: Review

References (24)

1. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, doubleblind, placebo-controlled trial. Lancet 2009; 374: 1503-11. [Erratum in: Lancet 2010; 375: 1436].
2. Jacobs LD, Beck RW, Simon J, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 34: 898-904.
3. Comi G, Filippi M, Barkhof F, Durrelli L, Edan G, Fernández O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82. (Pubitemid 32488815)
4. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. BENEFIT Study Group. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987-97.
5. Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, et al. NORdic trial of oral methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 2009; 8: 519-29.
6. Ravnborg M, Sorensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9: 672-80.
7. Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL III, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 2009; 72: 535-41.
8. Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen J, et al. No beneficial effect of simvastatin as add-on therapy to interferon-beta-1a for the treatment of relapsing-remitting multiple sclerosis: results of a large double blind, randomised, placebo-controlled trial. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Gothenburg, Sweden, 13-16 October 2010.
9. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8: 254-60.
10. Vermersch P, Foley J, Gold R, Kappos L, Olsson T, Bozic C, et al. Overview of clinical outcomes in cases of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 2010; 16: S7-39 [abstract 112].
11. Coles A, on behalf of the CAMMS223 Study Group. Alemtuzumab long-term safety and efficacy: five years of the CAMMS223 Trial. Mult Scler 2010; 16: S41-196 [abstract P410].
12. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-88. (Pubitemid 351240747)
13. Riester K, Sheridan J, Zhang Y, O'Neil G, Elkins J. Daclizumab treatment and CD56bright NK cell counts independently predict being lesion-free on brain MRI scans: results from the phase 2 CHOICE trial. Mult Scler 2010; 16: S41-196 [abstract P557].
14. Sorensen PS, Drulovic J, Havrdova E, Lisby S, Graff O, Shackelford S. Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing-remitting multiple sclerosis (RRMS) -24-week results of a phase II study. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Gothenburg, Sweden, 13-16 October 2010.
15. Brown MG, Skedgel C, Andreou P, Kirby S, Murray TJ. Natural history of EDSS, HRQoL and QALY progression in relapsing-onset MS in Nova Scotia, 1979-1998. Mult Scler 2010; 16: S41-196 [abstract P608].
16. Vukusic S, Passante N, Abdelali A, Dufour M, Frangoulis B, Van Ganse E. TYSEDMUS: observational prospective follow-up study of patients with MS and treated with natalizumab in France using the French EDMUS (European Database for Multiple Sclerosis) network. Mult Scler 2010; 16: S7-39 [abstract 67].
17. Le PE, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008; 79: 52-6.
18. Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008; 14: 663-70. (Pubitemid 351954409)
19. Edan G. Cytotoxic therapeutic agents in MS. Mult Scler 2010; 16: S7-39 [abstract 110].
20. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74: 1463-70.
21. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-33.
22. Subramanyam M, Plavina T, Simon K, Wilson E, Berman M, Schlain B, et al. Factors associated with anti-JCV antibody prevalence in a large cohort of natalizumab-treated MS patients. Mult Scler 2010; 16: S197-352 [abstract 138].
23. Miller D, Weber T, Montalban X, Grove R, Dua P, Wardell C, et al. Phase II trial of firategrast shows that oral antialpha4 therapy can suppress new MRI lesions in relapsing-remitting multiple sclerosis. Mult Scler 2010; 16: S7-39 [abstract 113].
24. Kappos L, Calabresi P, O'Connor P, Bar-Or A, Li D, Barkhof F. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: results of a phase II randomised placebo-controlled multicentre trial. Mult Scler 2010; 16: S7-39 [abstract 114].